Logo image of LFST

LIFESTANCE HEALTH GROUP INC (LFST) Stock Fundamental Analysis

NASDAQ:LFST - Nasdaq - US53228F1012 - Common Stock - Currency: USD

5.88  +0.04 (+0.68%)

After market: 5.9 +0.02 (+0.34%)

Fundamental Rating

3

LFST gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. While LFST seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, LFST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LFST has reported negative net income.
In the past year LFST had a positive cash flow from operations.
In the past 5 years LFST always reported negative net income.
In multiple years LFST reported negative operating cash flow during the last 5 years.
LFST Yearly Net Income VS EBIT VS OCF VS FCFLFST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

LFST has a Return On Assets of -1.68%. This is comparable to the rest of the industry: LFST outperforms 44.12% of its industry peers.
With a Return On Equity value of -2.43%, LFST perfoms like the industry average, outperforming 50.98% of the companies in the same industry.
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROIC N/A
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
LFST Yearly ROA, ROE, ROICLFST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LFST so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LFST Yearly Profit, Operating, Gross MarginsLFST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

More info and screens

4

2. Health

2.1 Basic Checks

LFST does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFST has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LFST has been increased compared to 5 years ago.
The debt/assets ratio for LFST is higher compared to a year ago.
LFST Yearly Shares OutstandingLFST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
LFST Yearly Total Debt VS Total AssetsLFST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

LFST has an Altman-Z score of 2.20. This is not the best score and indicates that LFST is in the grey zone with still only limited risk for bankruptcy at the moment.
LFST has a Altman-Z score (2.20) which is in line with its industry peers.
LFST has a debt to FCF ratio of 2.80. This is a good value and a sign of high solvency as LFST would need 2.80 years to pay back of all of its debts.
LFST's Debt to FCF ratio of 2.80 is fine compared to the rest of the industry. LFST outperforms 79.41% of its industry peers.
LFST has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
LFST has a Debt to Equity ratio of 0.19. This is in the better half of the industry: LFST outperforms 69.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Altman-Z 2.2
ROIC/WACCN/A
WACC8.9%
LFST Yearly LT Debt VS Equity VS FCFLFST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
With a Current ratio value of 1.47, LFST perfoms like the industry average, outperforming 51.96% of the companies in the same industry.
A Quick Ratio of 1.47 indicates that LFST should not have too much problems paying its short term obligations.
LFST has a Quick ratio (1.47) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.47
LFST Yearly Current Assets VS Current LiabilitesLFST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

LFST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.17%, which is quite impressive.
LFST shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.31%.
Measured over the past years, LFST shows a very strong growth in Revenue. The Revenue has been growing by 42.55% on average per year.
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%

3.2 Future

Based on estimates for the next years, LFST will show a very strong growth in Earnings Per Share. The EPS will grow by 40.71% on average per year.
The Revenue is expected to grow by 12.39% on average over the next years. This is quite good.
EPS Next Y47.18%
EPS Next 2Y40.97%
EPS Next 3Y40.71%
EPS Next 5YN/A
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LFST Yearly Revenue VS EstimatesLFST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B 2B
LFST Yearly EPS VS EstimatesLFST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LFST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LFST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFST Price Earnings VS Forward Price EarningsLFST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K -2.5K

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LFST indicates a slightly more expensive valuation: LFST is more expensive than 60.78% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, LFST is valued a bit cheaper than the industry average as 63.73% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.45
EV/EBITDA 52.62
LFST Per share dataLFST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as LFST's earnings are expected to grow with 40.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.97%
EPS Next 3Y40.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LFST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFESTANCE HEALTH GROUP INC

NASDAQ:LFST (6/9/2025, 5:18:39 PM)

After market: 5.9 +0.02 (+0.34%)

5.88

+0.04 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners35.32%
Inst Owner Change2.27%
Ins Owners6.62%
Ins Owner Change1.75%
Market Cap2.29B
Analysts81.33
Price Target8.89 (51.19%)
Short Float %7.17%
Short Ratio5.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.99%
Min EPS beat(2)43.98%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)10.6%
Max EPS beat(4)100%
EPS beat(8)5
Avg EPS beat(8)9.87%
EPS beat(12)8
Avg EPS beat(12)7.21%
EPS beat(16)8
Avg EPS beat(16)-4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.11%
Min Revenue beat(2)-1.94%
Max Revenue beat(2)1.72%
Revenue beat(4)2
Avg Revenue beat(4)0.16%
Min Revenue beat(4)-1.94%
Max Revenue beat(4)1.72%
Revenue beat(8)4
Avg Revenue beat(8)0.56%
Revenue beat(12)6
Avg Revenue beat(12)0.23%
Revenue beat(16)8
Avg Revenue beat(16)0.04%
PT rev (1m)-1.35%
PT rev (3m)-3.17%
EPS NQ rev (1m)11.76%
EPS NQ rev (3m)-50%
EPS NY rev (1m)11.62%
EPS NY rev (3m)32.36%
Revenue NQ rev (1m)-2.1%
Revenue NQ rev (3m)-1.34%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.78
P/FCF 22.45
P/OCF 18.16
P/B 1.57
P/tB N/A
EV/EBITDA 52.62
EPS(TTM)-0.1
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.26
FCFY4.45%
OCF(TTM)0.32
OCFY5.51%
SpS3.3
BVpS3.75
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.68%
ROE -2.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 7.93%
ROA(3y)-7.14%
ROA(5y)-11.82%
ROE(3y)-10.38%
ROE(5y)-16.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 2.8
Debt/EBITDA 5.68
Cap/Depr 38.82%
Cap/Sales 1.88%
Interest Coverage N/A
Cash Conversion 259.18%
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.47
Altman-Z 2.2
F-Score7
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)65.59%
Cap/Depr(5y)98.78%
Cap/Sales(3y)4.95%
Cap/Sales(5y)7.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y47.18%
EPS Next 2Y40.97%
EPS Next 3Y40.71%
EPS Next 5YN/A
Revenue 1Y (TTM)16.31%
Revenue growth 3Y23.29%
Revenue growth 5Y42.55%
Sales Q2Q%10.83%
Revenue Next Year14.17%
Revenue Next 2Y14.06%
Revenue Next 3Y14.2%
Revenue Next 5Y12.39%
EBIT growth 1Y92.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year429.54%
EBIT Next 3Y96.96%
EBIT Next 5YN/A
FCF growth 1Y682.28%
FCF growth 3YN/A
FCF growth 5Y98.76%
OCF growth 1Y202.74%
OCF growth 3Y124.79%
OCF growth 5Y44.39%